Hospitals | May 20, 2022
Sparsh Hospital introduces ‘Infinite care’ joint replacement programme
‘Infinite Care’ comprises two key pillars - Sparsh Sankalpa and Sparsh Sukshema
‘Infinite Care’ comprises two key pillars - Sparsh Sankalpa and Sparsh Sukshema
According to IQVIA sales data for the 12-month period ending March 2022, the Zytiga tablets, 500 mg market achieved annual sales of approximately US $ 260.2 million
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
Risk management plans can serve as a safeguard, helping manufacturers prepare for and respond to hazards that could lead to drug supply disruptions and shortages
The partnership will further strengthen Olympus leadership in the diagnosis and staging of liver disease
Dxcover announced that it will be presenting new data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3-7
A primary investment of Rs 194.4 crore has been made
Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
Expansion of leading biomarker and bioanalysis company enhances bioanalytical solutions for targeted radiopharmaceuticals
Subscribe To Our Newsletter & Stay Updated
